GVS SPA

Their core work

GVS is a large Italian filtration and membrane technology manufacturer headquartered near Bologna. Their core business is designing and producing advanced filtration solutions — from polymer membranes to climate-control systems — serving automotive, biomedical, and industrial sectors. In H2020, they contributed membrane and filtration expertise to projects ranging from electric vehicle climate systems to antibody purification and nanostructured polymer development. Their participation in training networks also signals investment in building the next generation of specialists in their technology domains.

What they specialise in

How they've shifted over time

GVS entered H2020 with a focus on industrial polymer and material science applications (TheLink, 2014) and automotive climate systems (XERIC, 2015). By their later projects, the focus shifted decisively toward biomedical applications — first membrane-based antibody purification (AMECRYS, 2016), then extracellular vesicle research for diagnostics and therapeutics (TRAIN-EV, 2017). This trajectory shows a company deliberately extending its membrane and filtration competence from automotive and industrial markets into life sciences and biopharma.

GVS is migrating its core filtration expertise toward high-value biomedical and pharmaceutical applications, making them an increasingly relevant partner for health and life science consortia.

How they like to work

GVS operates primarily as a participant (3 of 4 projects), contributing specialized industrial filtration know-how to research-led consortia. They coordinated one significant project (XERIC), demonstrating they can lead when the topic aligns closely with their core product line. With 37 unique partners across 13 countries, they maintain a broad European network rather than relying on a fixed set of repeat collaborators.

GVS has collaborated with 37 distinct partners across 13 European countries, reflecting a broad and diverse network for a company with only four H2020 projects. Their partnerships span academic training networks and applied research consortia alike.

What sets them apart

GVS brings something rare to EU consortia: large-scale manufacturing capability in advanced filtration combined with genuine R&D engagement. Unlike pure research partners, they can take membrane innovations from lab to production. Their cross-sector versatility — automotive, pharma, biomedical — means they can bridge disciplines that rarely talk to each other, making them a strong industrialization partner for projects that need to demonstrate real-world application of membrane-based technologies.

Highlights from their portfolio

• XERIC
  Their only coordinated project and largest single grant (EUR 1.03M), targeting a commercially concrete goal: extending EV range through better climate-control systems.
• AMECRYS
  Represents their pivot into biopharma — applying membrane expertise to the high-value problem of monoclonal antibody purification.
• TRAIN-EV
  Shows GVS investing in emerging biomedical science (extracellular vesicles) as an industry training partner, signaling long-term strategic interest in diagnostics and therapeutics.